Question: Does a polygenic score for Schizophrenia (SCZ) predict response to lithium in patients with Bipolar Disorder (BPD)? What are the molecular drivers of the association between SCZ and lithium treatment response?
ABSTRACT
Importance: Lithium is a first-line mood stabilizer for the maintenance treatment of Bipolar Disorder (BPD). However, the efficacy of lithium varies widely, with a non-response rate of up to 30%. Biological response markers and predictors are lacking.
Objective: Genetic factors are thought to mediate lithium treatment response, and the previously reported genetic overlap between BPD and schizophrenia (SCZ) led us to test whether a polygenic score (PGS) for SCZ could predict lithium treatment response in BPD.
Further, we explored the potential molecular underpinnings of this association.
Design: Weighted SCZ PGSs were computed at ten p-value thresholds (PT) using summary statistics from a genome-wide association study (GWAS) of 36,989 SCZ cases, and genotype data for BPD patients from the Consortium on Lithium Genetics (ConLi + Gen). For functional exploration, we performed a cross-trait meta-GWAS and pathway analysis, combining GWAS summary statistics on SCZ and lithium treatment response.
Setting: International multicenter GWAS.
Participants: Patients with BPD who had undergone lithium treatment were genotyped and retrospectively assessed for long-term treatment response (n=2,586).
Main outcome measures:
Clinical treatment response to lithium was defined on both the categorical and continuous scales using the ALDA score. The effect measures include odds ratios (ORs) and the proportion of variance explained (R 2 ), and a significant association was determined at p<0.05.
Results:
The PGS for SCZ was inversely associated with lithium treatment response in the categorical outcome (p=8x10 -5 ), at PT <5x10 -2 . Patients with BPD who had low polygenic load for SCZ responded better to lithium, with ORs for lithium response ranging from 3.46
INTRODUCTION
Bipolar Disorder (BPD) is a severe and often disabling psychiatric condition, characterized by recurrent dysregulation of mood with episodes of mania and depression. With an early disease onset and an estimated lifetime prevalence of 1% 1 to 4.4% 2 , BPD is associated with high personal impairment and societal costs, accounting for 9.9 million years of life lived with disability worldwide 3 , and substantially increased all-cause mortality and risk of suicide 4 . The etiology of BPD is complex, and both genetic and environmental factors have been shown to contribute to the pathogenesis of the disorder 5 . The estimated heritability of BPD ranges from 60% to 85% 6 , and candidate gene 7 and genome-wide association studies (GWASs) [8] [9] [10] [11] [12] have successfully identified genetic loci implicated in the illness. However, only a small fraction of the heritability is accounted for by replicated genetic variants that have been identified so far 7 .
Lithium stabilizing properties were discovered by Australian psychiatrist John Cade back in 1949 13 . Since then, it has retained a status as the 'gold standard' mood stabilizer 14, 15 , possessing unique protective effects against both manic and depressive episodes 16 , as well as for suicide prevention 17 . Consequently, lithium is recommended as first-line maintenance treatment for BPD by several clinical practice guidelines [18] [19] [20] [21] . However, there is significant inter-individual variation between lithium treatment responders and non-responders. About 30% of patients are only partially responsive, and more than a quarter show no clinical response at all 22 . While clinical studies report a combination of demographic and clinical characteristics as potential predictors of treatment response in patients with BPD 23 , genetic factors also appear to be highly involved 22, [24] [25] [26] . So far, three GWASs have successfully identified single nucleotide polymorphisms (SNPs) associated with lithium treatment response in BPD pointing to different genetic loci 22, 27, 28 . To improve the understanding of the molecular mechanisms underlying the therapeutic effects of lithium, alternative genomic approaches can complement GWAS deserve consideration. One such approach is polygenic analysis, which quantifies the combined effects of genetic variants across the whole genome on a given clinical outcome, computed as a weighted summation of effect sizes of multiple independent polymorphisms. An accurate and successful polygenic model may assist early screening for disease risk, clinical diagnosis, and the prediction of treatment response and prognosis. In the current study, we aimed to investigate whether BPD patients with high trait genetic susceptibility for schizophrenia (SCZ), expressed by their SCZ polygenic score (PGS), would respond better or more poorly to lithium compared to BPD patients with a low PGS for SCZ. Additionally, we set out to explore the genetic and molecular underpinnings of any identified association between SCZ and lithium treatment response. A number of previous observations motivated this approach. First, there is increasing evidence for a substantial genetic overlap between BPD and SCZ. The Psychiatric Genomics Consortium (PGC) estimated a shared genetic variation of ~68%, which is the highest among all pairs of psychiatric diagnoses 27 . Consistent with this, several shared risk genes and shared biological pathways associated with both disorders have been identified 28, 29, 30 , and current sample sizes for SCZ far exceed those available for BPD and thus are better powered. Second, despite these genetic and molecular commonalities, lithium is not an effective medication for people suffering from SCZ 31 , and increased SCZ trait loading in those with BPD might be expected to serve as a predictor for poor treatment response. An earlier family study found an association between family history of schizophrenia and poor response to lithium 32 Third, during acute illness episodes, BPD and SCZ are often difficult to distinguish clinically because of overlapping psychotic symptoms such as hallucinations, delusions, and disorganization, as well as some common behavioral disturbances such as irritability or anger 33 . Aiming to predict response to lithium, which could potentially confer advantages for patients and their treating physicians 34 we sought to evaluate the aggregated effect of genome-wide SNPs for SCZ on lithium treatment response in BPD using a polygenic score approach that was based on the results of the largest SCZ GWAS to date 35 . Further, in order to explore potential genetic and molecular drivers of any detected association, we carried out a cross-trait GWAS meta-analysis, combining the summary statistics from the largest available GWAS for both SCZ 35 and lithium response 22 . Overlapping SNPs that met genome-wide significance in the meta-GWAS were subsequently analyzed for biological context using the Ingenuity® Pathway Analysis platform (IPA®).
METHODS AND MATERIALS

Study Samples
The International Consortium on Lithium Genetics (ConLi + Gen) 22, 36 . A series of quality control procedures were implemented on the genotype data before and after imputation as described below.
Genotyping and quality control
The genome-wide genotypes, as well as clinical and demographic data, were collected by 22 participating sites. Quality control (QC) procedures were implemented using PLINK 37 .
Samples with low genotype rates <95%, sex inconsistencies (X-chromosome heterozygosity), and genetically related individuals were excluded. We also excluded SNPs that had a poor genotyping rate (<95%), an ambiguity (A/T and C/G SNPs), a low minor allele frequency (MAF<1%), or that showed deviation from Hardy-Weinberg Equilibrium (p<10 -6 ).
Imputation
The genotype data passing QC were imputed on the Michigan server 38 (https://imputationserver.sph.umich.edu) separately for each genotype platform using the 1000 Genomes Project Phase 3 (Version 5) reference panel. During the imputation process, we used the European reference panel for all the samples except for those from Japan and Taiwan, for which the East Asian reference population was used. After excluding the lowfrequency SNPs (MAF<10%); low-quality variants (imputation INFO < 0.9); and indels, the imputed dosages were converted to best guess genotypes. The subsequent polygenic analyses were performed using the best guess genotypes.
Discovery GWAS summary data
The PGSs were calculated using the approach previously described by the International Schizophrenia Consortium 39 . This method requires discovery and target datasets. The discovery data, which refers to the GWAS summary statistics-effect sizes (beta, a log of odds ratio), were obtained from a previously published SCZ GWAS 35 that was publicly available for download by the Psychiatric Genomics Consortium (PGC)
http://www.med.unc.edu/pgc/, accessed on March 18, 2017.
Target outcome
Lithium treatment response in BPD was defined for patients who had received lithium for a minimum of 6 months. Lithium treatment outcome was assessed using the "Retrospective
Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale, also known as the ALDA scale 40, 41 . The ALDA scale is a well-validated tool to rate symptom improvements after treatment with lithium in BPD, and it has shown excellent inter-rater reliability 42 . The ALDA scale quantifies symptom improvement over the course of treatment (A score, range 0-10), which is then weighted against five criteria (B score) that assess confounding factors, each scored 0, 1, or 2. The total score is calculated by subtracting the total B score from the A score, and negative scores are set to zero 22 . We developed two main outcomes for lithium response (categorical and continuous outcome).
The categorical (i.e., good versus poor) response to lithium in BPD was defined based on the total score as a cut-off score of 7, in which patients with a total score of 7 or higher were categorized as "responders". The ALDA score on subscale A was used as a continuous outcome after excluding individuals with a total B score greater than 4 or who had missing data on the total scores of ALDA subscale A or B 22 . In addition to the ALDA scale scores, information on covariates such as age and gender was collected, and further details can be found in an earlier publication 22 .
Polygenic scoring
Quality-controlled SNPs were clumped for linkage disequilibrium based on GWAS association p-value informed clumping using r 2 = 0.1 within a 250-kb window to create a SNP-set in linkage equilibrium using PLINK software run on Linux (plink --clump-p1 1 -- A genome-wide weighted SCZ PGS for each participant was calculated at each p-value threshold (PT) as the sum of independent SNPs genotype dosage (from 0 to 2) of the reference allele in the ConLi + Gen genotype data, multiplied by SCZ GWAS effect sizes for the reference allele, estimated as log (OR) divided by the total number of SNPs in each threshold.
STATISTICAL ANALYSES
For statistical analyses, we applied PGS association analyses, cross-trait meta-GWAS, and
Ingenuity Pathway Analysis (IPA) of the cross-trait findings. The details for each analysis are described below.
Polygenic score association analysis
Once the PGSs were constructed, the association of the PGSs at each PT and lithium treatment response was evaluated using regression models. While a binary logistic regression was implemented for the categorical outcome (response versus non-response), a linear regression was applied to lithium treatment response on the continuous scale. Using the PGS at the most significant threshold (PT <5x10 -2 ), we divided the study samples into ten deciles (1 st to 10 th ), ranging from the lowest polygenic load (1 st decile) to the highest polygenic load (10 th decile). The most significant threshold refers to the PT at which the PGS for SCZ and lithium treatment outcomes were most strongly associated (i.e., the smallest p-value). Using binary logistic and linear regression modeling, we compared BPD patients with lower polygenic load (1 st to 9 th deciles) for SCZ with patients with the highest polygenic load (10 th decile), to quantify the effect of SCZ polygenic load on lithium treatment outcomes. Associations were considered significant at p < 0.05.
The PGS association analyses were adjusted for the covariates age, gender, genotyping platform, and 7 principal components (PCs) calculated in PLINK. The analyses were performed using R for Statistical Computing and PLINK 1.9 for Linux 37 . Prediction accuracy, the percentage of variance in lithium response accounted by for the PGS at each PT, was estimated as the variance explained by the full model including each PGS and covariates minus the variance explained by the model including only covariates.
Cross-trait meta-analysis of genome-wide association studies
Biologically, a significantly associated PGS implies that genetic factors influencing the two traits are overlapping. Thus, further analyses were performed to identify genetic polymorphisms that are likely to both increase the susceptibility to SCZ and influence treatment response to lithium in patients with BPD. We performed cross-trait meta-analyses by combining the summary statistics for GWAS on lithium response from the ConLi + Gen 22 and GWAS on SCZ from the PGC 35 . We applied both the O'Brien's (OB) method and the direct Linear Combination of dependent test statistics (dLC) approach 43, 44 , which are implemented in the C ++ eLX package. Briefly, the OB and dLC approach, combine univariate meta-GWAS data (beta coefficients or Z-scores) for each SNP 43, 44 .
The methods follow an inverse-variance meta-analysis approach and directly combine correlated Z-scores (as in meta-analyses) considering the correlation within the univariate test statistics and estimated variances between the traits. The OB method is more powerful when the summary statistics are homogeneous (not very different) and in the similar direction, while dLC is better when the test statistics are either heterogeneous or in opposite directions. Because they often vary based on the sign of the Z-scores, the smallest p-value on either of the two tests could be used to determine statistical significance. Further details are available elsewhere 43, 44 .
In this cross-trait meta-analysis, for each SNP we combined GWAS association Z-scores from the SCZ study 35 with the GWAS association Z-scores for lithium treatment response in the ConLi + Gen study 22 
Ingenuity® Pathway Analysis (IPA®)
To characterize the potential biological significance of the SNPs discovered from the crosstrait meta-analyses, we performed analyses using QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, CA, USA, www.qiagen.com/ingenuity).
To prepare the input genes for IPA, we followed a three-step bioinformatics approach:
Step 1: We defined tagSNPs that are in high linkage disequilibrium (LD: r 2 >0.5) and within a + 500-kb region with the meta-GWAS significant SNPs (gSNPs) using the genetic catalog of the 1000 Genomes project phase 3, October 2014 release 45 .
Step 2: The gSNPs and tagSNPs from step 1 were mapped to the genes in which they are located. This generated a list of hosting genes (hGenes).
Step 3: We performed an expression quantitative trait loci (eQTL) lookup in three databases, searching for any nearby genes (eGenes) whose expression was associated with each of the gSNPs and tagSNPs from step-1. These databases contained the results of eQTL-mapping studies from blood and/or brain tissues: 1) Westra et al 46 Finally, the combined list of hGenes and eGenes was used as input into the IPA software after removing gene duplicates. IPA compares the proportion of input genes mapping to a biological pathway to the reference genes list in the ingenuity databases. The significance of the overrepresented canonical pathways and functional networks is determined using the right-tailed Fisher's exact test and later adjusted for multiple testing using the BenjaminiHochberg (BH) method 48 . Significant results were determined at BH adjusted P-value <0.01. ALDA score for all participants was 4.9 (3.1) ( Table 1) . Subjects with total B score >4 or who had missing data on the total scores on ALDA subscale A or B were excluded.
RESULTS
Sample characteristics and lithium treatment response rates
Associations of SCZ PGS with lithium treatment response in BPD patients
At the most significantly associated threshold (PT <5x10 -2 ), the PGS for SCZ was strongly associated with lithium treatment response in BPD (p=8x10 -5 ) for the categorical outcome on the ALDA scale (Figure 1 ), explaining 0.8% of the variance. For the continuous outcome (total score on the ALDA subscale A), the direction of association was congruent with the finding on the categorical outcome, but was not statistically significant (p>0.05). The association results of the categorical and continuous outcomes at each threshold levels are detailed in Figure 1 . In each threshold, a lower polygenic load for SCZ was associated with a favorable lithium treatment response in patients with BPD (Table 2 & Figure 1 ). Figure 1 ). +-FAM177A1 A1, effect allele; A2, other allele; Effect direction: the effect of the SNPs on schizophrenia and lithium treatment response oriented to the reference allele. Nearest genes were based on refseq genes (build 37). To characterize the functional implications of identified SNPs, we undertook IPA pathway analysis using query gene inputs generated from the results of the cross-trait and eQTL analyses. These genes included 33 hGenes hosting the gSNPs and tagSNPs, as well as the eQTL genes identified from the three databases -27 eGenes from Westra et al, 23 eGenes from Almanac (Braineac) and 31 eGenes in GTEx portal. Table 4 gives the list of 82 unique genes used as input for IPA. IFITM4P  IGBP1P1  HLA-DMA  LOC100128364  MVK  IGBP1P1, KCTD10,  KIAA0391  SRP54  HLA-DOB  LOC285830  EFTUD1P1  KIAA1920, LMAN2L  FAM177A1  LMAN2L  LOC440297  GOLGA6L4  LOC100128364, LOC285830  PPP2R3C  GABBR1  LOC440300  CHRNA2  LOC440297, LOC440300  KIAA0391  PSMB9  LOC642288  IGBP1P1  LOC642288, LOC727858  PSMA6  BRD2  LOC727858  BAZ1A  LOC728121, MEF2C, MICD ADAMTSL3  MEF2C  LOC728121  MICE  MICE, MIC, MMAB, MVK  GOLGA6L5P PPP2R3C  HCG4P5  MYO1H,NACAD, NMB  UBE2Q2P1  CMAHP  MICD  PPP1R11, PPP2R3C, PSMA6  ZSCAN2  GPNMB  HLA-G  PSMB9, SCAND2P, SEC11A  SCAND2P  SEC14L3  HLA-T  SEC14L3, SRP54, TAP2  WDR73  GOLGA6L5P TMEM161B, TRIM26, TRIM35  NMB  HFE  UBE2Q2P1, UBE3B  SEC11A  CASP14  WDR73, ZFP57, ZNF592  ZNF592 AC103965.1 ZNF804A, ZNRD1 GPNMB ZNRD1ASP, ZSCAN2 LOC440300 We then assessed how these genes are enriched with canonical pathways in the Ingenuity database. The most significantly represented canonical pathways and enriched genes are shown in Table 5 Legend: a P-values were adjusted by Benjamini & Hochberg (BH) method 48 .The top canonical pathways and enriched genes are determined at BH adjusted P-value <0.01.The P-value reflects the likelihood that the association between a set of input genes and a given canonical pathways are statistically significant.
Brief description: OX40-is a member of the tumour necrosis factor receptor (TNFR) -superfamily; Cdc42-Cell division control protein 42 homolog is a protein involved in regulation signalling pathways that control cellular functions including cell morphology, cell migration, endocytosis and cell cycle progression; Nur77 is a member of nuclear receptor family involved in mediating inflammatory responses and it also induces apoptosis; Th1/Th2 are pathways related to type 1 and type 2 T helper cells that play a vital role in the adaptive immune system. These pathways regulate immune responses by releasing T cell cytokines.
The IPA® network analysis revealed 2 relevant functional networks (Table 6 ). As it can be seen in Figure 3 , the top 2 networks indicate that tumor necrosis factor alpha (TNFα), Interleukin-4 (IL-4), and interferon gamma (IFNγ) might represent important functional molecular nodes in the interaction between lithium response and SCZ. Table 6 .
Legend Figure 3 : IPA generates the network using a proprietary algorithm, and included genes that could contribute to the network, even if they were not contained in the original dataset. Legend: The molecules represented in bold are derived from the cross-trait meta-GWAS (Table 1) and post-GWAS analysis (Supplementary Tables). The p-score is calculated by IPA, and estimates, the probability of finding eleven (group 1) or ten (group 2) or more focus molecules in a network of 35 molecules randomly selected from IPA's Global Molecular Network. The p-score = −log10 (p-value); the p-value is calculated by Fisher's exact test.
DISCUSSION
The present study reports two main findings: first, using PGS methodology, we demonstrate that there is an inverse association between genetic loading for SCZ risk variants and longterm therapeutic response to lithium in patients with BPD on the categorical outcome of the ALDA scale. Second, we show in cross-trait meta-GWAS and pathway analyses that genetic variants in the HLA region, the antigen presentation pathway and inflammatory cytokines such as TNF-α, IL-4 and IFNγ could have a biological role in lithium treatment response in BPD.
These findings are consistent with previous clinical and epidemiological studies of lithium response. Lithium is not an effective medication for people suffering from SCZ spectrum disorders 49, 31 . Moreover, lithium may be deleterious for patients with SCZ because of their greater liability to developing lithium-induced neurotoxicity even at modest doses and blood levels 49, 50 . The severity of psychotic symptoms present in bipolar patients was found inversely associated with lithium treatment response 51 . Similarly, slow resolution of psychosis in response to lithium treatment during acute manic episodes has been shown to predict poorer overall response to the drug 52 . Amongst patients with BPD, those with a family history of SCZ show poorer response to lithium compared to those with a family history of BPD 53 . Our findings may provide insight into the genetic architecture underlying these clinical observations.
In the SCZ to lithium response cross-trait GWAS meta-analyses, 15 genetic loci located within protein-coding, genes that appear to have overlapping effects on SCZ risk and response to lithium treatment in BPD were identified. Only one of these genes, type 1 adenylyl cyclase (ADCY1), had previously been directly implicated in genetic studies of both SCZ 54 and lithium treatment response 26 . It has been shown that ADCY1 directs neuronal signaling through activation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phosphoinositide 3-kinase (PI3K) pathways 55 . Lithium, in turn, has also been shown to engage the ERK 1/2 pathway and the PI3K pathway, possibly through complex interactions with GSK-3 56, 57 . It is possible that the polymorphisms in the ADCY1 gene implicated in our study result in altered ERK1/2 and PI3K activation states, thereby interfering with potentially therapeutic lithium effects through these pathways.
Both the most significant finding of the cross-trait GWAS (HCG4 gene on chromosome 6) and the SNPs from the post-GWAS functional analyses point out to the HLA system in modulating lithium response. Differences in cellular HLA surface protein composition between BPD patients who respond well to lithium and non-responders were first reported over 30 years ago in several studies. These reports noted that leukocyte HLA-A3 antigen reactivity was reported to be associated with poor lithium response, whereas the absence of HLA-A3 predicted a favorable response [58] [59] [60] . At the same time, in vitro experiments suggested that lithium binds to HLA antigens on cultured human leukocytes 61 . A subsequent in vivo study in BPD patients demonstrated that exposure to lithium for about 2 months promoted substantial alterations in the composition of leukocyte HLA proteins 62 .
The genetic association between SCZ and the HLA region on chromosome 6 is the most robust finding of SCZ GWAS to date 35, [63] [64] [65] [66] Interestingly, a recent study demonstrated that lithium exposure of human monocytes and mouse microglia in vitro resulted in increased expression of C3, which in turn was driven by the inhibition of glycogen synthase kinase-3 (GSK-3) 68 . Inhibition of GSK-3 is to date the most comprehensively documented molecular effect of lithium in neurons, glia, and peripheral immune cells 69, 70 . Taken together, these studies and our findings raise the possibility that lithium's GSK-3-mediated activation of the complement system, via enhanced C3 expression 68 , is suppressed in people with a high genetic loading for SCZ due to functional disturbances of the complement cascade resulting from the SCZ-HLA-C4
association. In this context, it is also compelling that IPA® identified Antigen Presentation as the top canonical pathway characterizing the findings of our cross-trait meta-GWAS analysis. Cellular antigen presentation is mediated by HLA proteins and is closely linked to the functions of the complement system as described above.
Further, functional network analysis of our meta-GWAS findings implicated TNFα, IL-4
and IFN-γ as central functional nodes, suggesting that the negative interaction between lithium response and genetic predisposition for SCZ could be mediated by mechanisms implicating these pro-inflammatory cytokines. Previous studies have reported modulatory effects of lithium treatment on these cytokines in BPD. For example, a study of euthymic patients with BPD reported that TNFα and IL-4 were selectively increased in patients on lithium monotherapy relative to untreated patients and healthy controls 71 This study has four limitations that are outlined in the Supplementary Materials.
Limitations of the study
Our study has a number of limitations. First, the polygenic load for SCZ accounted for only a modest percentage (~1%) of the observed variation in lithium treatment response in patients with BPD. While this is in line with previous reports on the effects of PGSs on complex clinical phenotypes such as SCZ and BPD 65 , the significance of this finding at clinical-and population-levels needs to be further explored. Encouragingly, previous studies indicate that PGS approaches can assist in characterizing relevant clinical phenotypes. For example, in SCZ, a high polygenic SCZ score has been reported as a measure of disease chronicity 83 , and is associated with failure to respond to treatment 84 . Second, lithium response in our study was assessed using the ALDA scale, which is a retrospective measure.
In order to substantiate our findings further, prospective studies are required that can measure clinical responses to lithium prospectively. Third, while our strategy for exploring the biological context of our genetic findings can point towards avenues for future research, it is not designed to provide definitive mechanistic answers. Hypothesis-driven experiments are required to follow up on these leads. Fourth, the Ingenuity Pathway Analysis revealed that the enriched pathways were mainly driven by two independent loci (rs209474 and rs144373461/rs142425863). As an example, the top associated "Antigen Presentation
Pathway" contains a total of 9 genes of which 6 are implicated by the SNP rs209474 (HLA- have a chromosomal distance of only 748 bp. This could be due to the high LD structure in the HLA region and also be related to the parameters used to define LD to extract tagSNPs to the meta-GWAS significant SNPs (LD: r 2 >0.5 and within a + 500-kb region). The same commonly used parameters were used for all significant findings without a priori stratification according to a chromosomal region.
In conclusion, we demonstrated for the first time that lower SCZ loading is strongly associated with better lithium response in patients with BPD. Follow-up functional analyses point to genes that code for the immune system, including the HLA complex and inflammatory cytokines. For future clinical translation, a high genetic loading for SCZ risk variants could be used in conjunction with clinical parameters to predict the likelihood of non-response to lithium treatment in BPD.
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